SQI Diagnostics' Q3 Loss Jumps 50 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Canadian microarray-based diagnostics development firm SQI Diagnostics today reported that its net loss for its fiscal third quarter increased 50 percent year over year.

For the three months ended June 30, the Toronto-based company's loss was C$2.7 million (US$2.8 million), or C$.08 per share, compared to C$1.8 million, or C$.06 per share, a year ago.

The firm did not disclose any revenues for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.